Literature DB >> 22861363

Down syndrome, autoimmunity and T regulatory cells.

F P Pellegrini1, M Marinoni, V Frangione, A Tedeschi, V Gandini, F Ciglia, L Mortara, R S Accolla, L Nespoli.   

Abstract

Autoimmune diseases are more represented in Down syndrome (DS) individuals compared to chromosomally normal people. Natural T regulatory cells (nT(reg) ) have been considered to be primary in the role of controlling the intensity and targets of the immune response. We have investigated the phenotypical and functional alteration of nT(reg) in a group of DS people. The phenotypical characteristic of T(reg) cells of 29 DS was analysed and compared with an age-matched healthy control group. The inhibitory potential of CD4(+) CD25(high) CD127(low) T regulatory cells was evaluated on autologous CD4(+) CD25(-) T cell proliferation in response to activation with a mytogenic pan-stimulus (anti-CD2, anti-CD3 and anti-CD28 antibodies). The CD4(+) CD25(high) cells in the DS and control groups were 2·692±0·3808%, n=29 and 1·246±0·119, n=29%, respectively (P=0.0007), with a percentage of forkhead box protein 3 (FoxP3)-expressing cells of 79·21±3·376%, n=29 and 59·75±4·496%, respectively (P=0.0015). CD4(+) CD25(+) FoxP3(+) cells were increased in peripheral blood from DS subjects (DS mean 5·231±0·6065% n=29, control mean 3·076±0·3140% n=29). The majority of CD4(+) CD25(high) were CD127(low) and expressed a high percentage of FoxP3 (natural T(reg) phenotype). While the proliferative capacity of DS T cells was not altered significantly compared to normal individuals, a reduced inhibitory potential of T(reg) compared to healthy controls was clearly observed (mean healthy control inhibition in T(eff)  : T(reg) 1:1 co-culture: 58·9%±4·157%, n=10 versus mean DS inhibition in T(eff) :T(reg) 1:1 co-culture: 39·8±4·788%, n=10, P=0.0075; mean healthy control inhibition in T(eff)  : T(reg) 1:0·5 co-culture: 45·10±5·858%, n=10 versus DS inhibition in T(eff) : T(reg) 1:0·5 co-culture: 24·10±5·517%, n=10, P=0.0177). DS people present an over-expressed peripheral nT(reg) population with a defective inhibitory activity that may partially explain the increased frequency of autoimmune disease.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22861363      PMCID: PMC3445000          DOI: 10.1111/j.1365-2249.2012.04610.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism.

Authors:  Alicia Benson; Sean Murray; Prashanthi Divakar; Nikolay Burnaevskiy; Reed Pifer; James Forman; Felix Yarovinsky
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: importance of assessing naive T-cell markers.

Authors:  Alan P Knutsen; Mei W Baker; M Louise Markert
Journal:  J Allergy Clin Immunol       Date:  2011-10-22       Impact factor: 10.793

3.  Low-dose IL-2 as a therapeutic agent for tolerance induction.

Authors:  Thomas R Malek; Alberto Pugliese
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

4.  Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells.

Authors:  Rafal Pacholczyk; Hanna Ignatowicz; Piotr Kraj; Leszek Ignatowicz
Journal:  Immunity       Date:  2006-08-03       Impact factor: 31.745

5.  American Academy of Pediatrics: Health supervision for children with Down syndrome.

Authors: 
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

6.  Prevalence of coeliac disease in Down's syndrome.

Authors:  J Carnicer; C Farré; V Varea; P Vilar; J Moreno; J Artigas
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-03       Impact factor: 2.566

7.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

Review 8.  Thymus, innate immunity and autoimmune arthritis: interplay of gene and environment.

Authors:  Shimon Sakaguchi; Satoshi Tanaka; Atsushi Tanaka; Yoshinaga Ito; Shinji Maeda; Noriko Sakaguchi; Motomu Hashimoto
Journal:  FEBS Lett       Date:  2011-10-21       Impact factor: 4.124

9.  Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study.

Authors:  Quanhe Yang; Sonja A Rasmussen; J M Friedman
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  TCR-based lineage tracing: no evidence for conversion of conventional into regulatory T cells in response to a natural self-antigen in pancreatic islets.

Authors:  Jamie Wong; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

View more
  38 in total

1.  Surgical Treatment for Congenital Heart Defects in Down Syndrome Patients.

Authors:  Fernando Cesar Gimenes Barbosa Santos; Ulisses Alexandre Croti; Carlos Henrique De Marchi; Alexandre Noboru Murakami; Juliana Dane Pereira Brachine; Bruna Cury Borim; Renata Geron Finoti; Moacir Fernandes de Godoy
Journal:  Braz J Cardiovasc Surg       Date:  2019 Jan-Feb

2.  The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases.

Authors:  M Rotondi; C Virili; S Pinto; F Coperchini; L Croce; N Brusca; M Centanni; L Chiovato
Journal:  J Endocrinol Invest       Date:  2019-08-12       Impact factor: 4.256

Review 3.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

4.  Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome.

Authors:  Katherine A Waugh; Paula Araya; Ahwan Pandey; Kimberly R Jordan; Keith P Smith; Ross E Granrath; Santosh Khanal; Eric T Butcher; Belinda Enriquez Estrada; Angela L Rachubinski; Jennifer A McWilliams; Ross Minter; Tiana Dimasi; Kelley L Colvin; Dmitry Baturin; Andrew T Pham; Matthew D Galbraith; Kyle W Bartsch; Michael E Yeager; Christopher C Porter; Kelly D Sullivan; Elena W Hsieh; Joaquin M Espinosa
Journal:  Cell Rep       Date:  2019-11-12       Impact factor: 9.423

Review 5.  Immunodeficiencies Associated with Abnormal Newborn Screening for T Cell and B Cell Lymphopenia.

Authors:  Soma Jyonouchi; Artemio M Jongco; Jennifer Puck; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2017-03-28       Impact factor: 8.317

Review 6.  Celiac Disease Revisited.

Authors:  João Calado; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2021-03-17

Review 7.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

8.  Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to an autoimmune phenotype.

Authors:  Gabriel Skogberg; Vanja Lundberg; Susanne Lindgren; Judith Gudmundsdottir; Kerstin Sandström; Olle Kämpe; Göran Annerén; Jan Gustafsson; Jan Sunnegårdh; Sjoerd van der Post; Esbjörn Telemo; Martin Berglund; Olov Ekwall
Journal:  J Immunol       Date:  2014-07-18       Impact factor: 5.422

9.  Screening Guidelines for Thyroid Function in Children With Alopecia Areata.

Authors:  Deepa Patel; Ping Li; Andrew J Bauer; Leslie Castelo-Soccio
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

10.  A Difficult and Rare Diagnosis of Autoimmune Enteropathy in a Patient Affected by Down Syndrome.

Authors:  Anne Depince-Berger; Clara Cremilieux; Melanie Rinaudo-Gaujous; Christian Genin; Benedicte de Freminville; Claude Lambert; J Bruneau; Stephane Paul
Journal:  J Clin Immunol       Date:  2016-04-12       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.